
Cardiovascular Systems CSII
Quarterly report 2022-Q4
added 02-09-2023
Cardiovascular Systems Deferred Revenue 2011-2026 | CSII
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.11 M | 2.4 M | 1.87 M | 1.76 M | 1.24 M | - | - | - | 59 K | 156 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.4 M | 59 K | 1.37 M |
Quarterly Deferred Revenue Cardiovascular Systems
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 525 K | 694 K | 2.11 M | 2.81 M | 2.72 M | 2.49 M | 2.4 M | 2.4 M | 2.08 M | 2.09 M | 1.87 M | 1.76 M | 1.66 M | 1.71 M | 1.76 M | 1.76 M | 1.52 M | 1.25 M | 1.24 M | 1.24 M | 1.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.81 M | 525 K | 1.77 M |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
Cutera
CUTR
|
10.4 M | - | -10.19 % | $ 1.99 M | ||
|
Bruker Corporation
BRKR
|
438 M | $ 38.78 | -1.25 % | $ 5.78 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
Acutus Medical
AFIB
|
401 K | - | -26.83 % | $ 2.62 M | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
621 K | - | - | $ 10.2 M | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
Cognyte Software Ltd.
CGNT
|
127 M | $ 8.15 | 4.22 % | $ 585 M | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
AdaptHealth Corp.
AHCO
|
59.8 M | $ 9.69 | 3.09 % | $ 1.31 B | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
6.64 M | $ 4.15 | 4.01 % | $ 155 M | ||
|
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | ||
|
FONAR Corporation
FONR
|
4.29 M | $ 18.51 | 0.05 % | $ 121 M | ||
|
AxoGen
AXGN
|
14 K | $ 29.17 | -2.21 % | $ 1.34 B | ||
|
Apyx Medical Corporation
APYX
|
500 K | $ 3.31 | 4.42 % | $ 115 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
33 | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B | ||
|
Accuray Incorporated
ARAY
|
82.3 M | $ 0.53 | 0.68 % | $ 54.5 M | ||
|
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | ||
|
Cytosorbents Corporation
CTSO
|
419 K | $ 0.79 | -1.24 % | $ 43 M | ||
|
Align Technology
ALGN
|
1.33 B | $ 183.14 | 0.27 % | $ 13.7 B | ||
|
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | ||
|
Butterfly Network
BFLY
|
16.1 M | $ 3.99 | 7.7 % | $ 845 M | ||
|
BIOLASE
BIOL
|
2.45 M | - | -13.19 % | $ 166 K | ||
|
InMode Ltd.
INMD
|
11.9 M | $ 13.58 | -0.18 % | $ 878 M | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
313 M | $ 72.75 | -1.49 % | $ 108 B | ||
|
IRadimed Corporation
IRMD
|
2.26 M | $ 105.22 | 0.89 % | $ 1.33 B | ||
|
IRIDEX Corporation
IRIX
|
2.4 M | $ 1.42 | -0.7 % | $ 22.9 M | ||
|
Helius Medical Technologies
HSDT
|
148 K | $ 2.31 | 16.67 % | $ 1.4 M | ||
|
Alphatec Holdings
ATEC
|
10.4 M | $ 13.05 | 0.23 % | $ 1.96 B |